The Open-label Observation of Oral Hexavalent Reassorted Rotavirus Live Attenuated Vaccine (Vero Cell) in Healthy Adults and Children, as Well as the Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity in Healthy Infants
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Rotavirus vaccine (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions
- Sponsors Sinovac Biotech
Most Recent Events
- 05 May 2025 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2024 According to SINOVAC media release, company anticipates by the first half of 2024, this trial has finished enrollment and vaccination of adults and children participants, and enrollment of infants participants is ongoing and expected to be finished in the third quarter of 2024.
- 07 May 2024 New trial record